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Background: Neoadjuvant endocrine therapy with an aromatase inhibitor has shown efficacy comparable to that
of neoadjuvant chemotherapy in patients with postmenopausal breast cancer. Preclinical and clinical studies have
shown that the antidiabetic drug metformin has anti-tumor activity. This prospective, multicenter, phase II randomized,
placebo controlled trial was designed to evaluate the direct anti-tumor effect of metformin in non-diabetic
postmenopausal women with estrogen-receptor (ER) positive breast cancer.
Methods/Design: Patients meeting the inclusion criteria and providing written informed consent will be
randomized to 24 weeks of neoadjuvant treatment with letrozole (2.5 mg/day) and either metformin (2000 mg/day)
or placebo. Target accrual number is 104 patients per arm. The primary endpoint will be clinical response rate, as
measured by calipers. Secondary endpoints include pathologic complete response rate, breast conserving rate, change
in Ki67 expression, breast density change, and toxicity profile. Molecular assays will be performed using samples
obtained before treatment, at week 4, and postoperatively.
Discussion: This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic,
postmenopausal patients with ER-positive breast cancer.
Trial registration: ClinicalTrials.gov Identifier NCT01589367
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Metformin, which is commonly used to treat type 2
diabetes, is a relatively safe drug with known pharma-
cokinetics and manageable toxicities. In addition, nu-
merous experimental, epidemiologic, observational, and
clinical studies have shown that metformin has anti-* Correspondence: hanw@snu.ac.kr
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reproduction in any medium, provided the ortumor effects [1]. For example, in a preclinical mouse
xenograft model, metformin reduced the effective dos-
ages of standard chemotherapeutic drugs and had pref-
erential effects on tumorigenic cells [2]. A retrospective
clinical study showed that patients taking metformin
during neoadjuvant chemotherapy had a higher patho-
logic complete response (pCR) rate than diabetic pa-
tients not taking metformin or non-diabetes patients
(24% vs 8% vs 16%, p = 0.02) [3,4]. Two potential mech-
anisms of anti-cancer action of metformin have been sug-
gested. First, metformin may directly activate adenosine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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stream inhibition of mTOR signaling and the consequent
suppression of cell proliferation [5-7]. Second, metformin-
induced decreases in circulating insulin and insulin-like
growth factor (IGF) concentrations may reduce the activa-
tion of the IGF-receptor signaling axis, resulting in de-
creases in growth promotion and mitogenesis [8-10].
Thus, the anti-cancer effects of metformin are mediated
through a systemic improvement in metabolic profile and
by directly targeting tumor cells [11,12].
Questions remain, however, about the clinical benefits
of metformin as an anti-cancer agent in patients with
breast cancer. Although one large-scale, phase III trial of
adjuvant metformin has been initiated in women with
breast cancer (NCIC CTG MA.32) [1], the accrual and
treatment process is still ongoing, and several years of
follow-up are needed to determine survival benefits. In
addition, little is known about the effects of metformin
on different subtypes of breast cancer or on the synergy
between metformin and concurrently administered sys-
temic agents. In addition, the optimal dosage of metformin
that shows maximal anti-tumor effects with acceptable
toxicities has not been determined. In this context, neoad-
juvant treatment is the most efficient setting to assess the
short-term in vivo effects of drug therapy in breast cancer
patients. Neoadjuvant endocrine therapy results in a com-
parable response but lower toxicity compared with neoad-
juvant chemotherapy in women with ER-positive breast
cancer [13]. In postmenopausal women, aromatase inhibi-
tors are associated with higher response rates than tamoxi-
fen [14,15]. A recent phase II trial found that neoadjuvant
treatment with everolimus, an mTOR inhibitor, plus letro-
zole resulted in a better response rate than letrozole alone
[16]. In addition, neoadjuvant metformin was shown to
lower Ki67 level [17]. These results suggested that metfor-
min may be effective, when combined with letrozole, in
postmenopausal women with ER-positive breast cancer.
We therefore designed and initiated a phase II clinical trial
evaluating the anti-tumor effect of neoadjuvant metformin
in postmenopausal women with ER-positive breast cancer




The goal of this study was to evaluate the benefits of com-
bining metformin and letrozole in the neoadjuvant treat-
ment of postmenopausal women with ER-positive breast
cancer. The primary end point is the rate of tumor re-
sponse (clinical response rate) at 24 weeks, determined by
measurements with calipers; changes in size on ultrasound,
mammography, and MRI will be used as secondary efficacy
assessments. Clinical response includes complete response
(CR) and partial response (PR) by RECIST v1.1 criteria.Study design
METEOR is a phase II, prospective, randomized, double-
blinded, placebo-controlled multicenter clinical trial.
Twenty-one centers belonging to the Korean Breast
Cancer Society Study Group are participating in this
study (KBCSG-013). Patients will be randomly assigned
(1:1) to receive letrozole 2.5 mg/day plus either metfor-
min or placebo for 24 weeks before surgery. The initial
dose of metformin will be 1000 mg/day for the first
week, followed by 1500 mg/day for the second week,
and 2000 mg/day from the third week onward. Patients
will be randomized sequentially, stratified by center,
with randomization codes. Block randomization will be
used (SAS 9.2) in cooperation with the Medical Research
Collaborating Center (MRCC) of Seoul National University
Hospital. All study personnel will be masked to treatment.
This study protocol has been approved by the Korea Food
and Drug Administration (KFDA) as well as the institu-
tional review board of each center, and was registered at
clinicaltrials.gov (NCT 01589367). Written informed con-
sent was obtained from all participants.
Eligibility criteria and sample size calculation
Eligible patients are postmenopausal women with histologi-
cally confirmed ER-positive, stage II or III, primary breast
cancer with palpable and clinically measureable tumors.
The target population is 208 women, 104 in each arm.
Sample size was calculated based on expected clinical re-
sponse rates (cRR) of 55% in the letrozole plus placebo arm
and 70% in the letrozole plus metformin arm, with α = 0.10
and 80% power and including an estimated 10% drop out
rate. ER positivity is defined as ≥10% nuclear staining by
immunohistochemistry or Allred score ≥3. Criteria for
determining menopause include bilateral oophorec-
tomy, age ≥60 years, or age <60 years and amenorrhea
for ≥12 months and FSH >30 mIU/ml. Patients with
diabetes (HbA1c ≥6.5% or fasting plasma glucose
(FPG) ≥126 mg/dL (≥7 mM)); clinical T4, N3, or M1
disease; bilateral cancer, or inflammatory breast cancer
will be excluded, as will patients with a history of lactic
acidosis or at high risk of having metformin-induced
lactic acidosis, such as those with high alcohol con-
sumption or NYHA class III/lV congestive heart failure.
Treatment schedule and evaluation
Patients will be randomly assigned (1:1) to 24 weeks of
neoadjuvant treatment with metformin plus letrozole or
placebo plus letrozole (Figure 1). Medications will be
distributed at each monthly visit, with compliance
assessed by counting the remaining tablets.
Tumor size will be measured clinically with calipers
before treatment and sequentially every month. Each pa-
tient will undergo a careful physical examination at each
monthly visit, and patients with progressive disease (PD)
Figure 1 Scheme of the METEOR trial. Patients meeting the
inclusion criteria will be 1:1 randomized to 24 weeks of letrozole plus
metformin or letrozole plus placebo. Core needle biopsies will be
recommended after 4 weeks of treatment. Surgery will be performed
within 2 weeks after the end of the 24 week treatment period.
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immediate surgery. Patients with stable disease (SD) will
be continued on treatment. Ultrasound-guided core nee-
dle biopsy samples will be obtained at the first visit and
after four weeks of medication, with Ki67 levels in these
samples centrally assessed. It is also recommended that
4-week blood samples be obtained to measure serum
biomarker concentrations. Surgery will be scheduled
within 2 weeks after completing the 24 weeks of medica-
tion. Tissue from surgical specimens will be collected
for further planned assessments of biomarkers by paired
analysis with the pretreatment and week 4 core needle
biopsy specimens. HbA1c, FPG, insulin, c-peptide, and
IGF-1 concentrations will be measured at baseline and
after 12 and 24 weeks of treatment. Mammography,
ultrasonography, and bilateral breast MRI will be per-
formed before starting medication and after completion
of treatment just before surgery.
Analysis of the results
The primary endpoint is cRR. Tumor response will be
assessed by RECIST criteria v1.1. Tumor size will be
measured by individual clinicians at monthly visits. The
secondary endpoint is pathologic complete response
(pCR), defined as the absence of invasive cancer at the
primary site and in the axilla. Before treatment, each pa-
tients will be categorized by surgeons into one of three
groups: 1) marginal for breast conservation, 2) candidate
for mastectomy only, and 3) inoperable by standardmastectomy [18]. Baseline assessment and actually per-
formed surgery will be compared. The breast conserva-
tion rate in each arm will be evaluated, and the toxicity
profile of each arm will be assessed every 4 weeks using
NCI-CTCAE version 4.0 (http://ctep.cancer.gov/report-
ing/ctc.html). All parameters will be collected and man-
aged using an e-clinical trial platform (MEBICA™).Translational research project
In addition to assaying Ki-67, phosphorylated S6 kinase
1 (p-S6K1) will be analyzed by immunohistochemistry
(IHC) in a central laboratory. Fresh frozen tissue of week
4 biopsies and final surgical specimens will be collected
from several major hospitals participating in this study.
These samples will be used for DNA microarray analysis
or whole transcriptome sequencing using next gener-
ation sequencing (NGS) technology. Phosphorylation of
AMPK(T172), expression of IR(insulin receptor) and
OCT1(Organic cation transporter) will be measured.
Assessment of apoptosis will be done by Miller-Payne
Grading system along with various commercialized kits.
We previously reported that breast density reduction
after short term adjuvant endocrine therapy was predict-
ive of recurrence-free survival [19]. We intend to analyze
the association between breast density reduction and re-
sponse to endocrine therapy in this prospective trial.
Pre- and post-medication mammography results and breast
MRI images of all patients will be centrally reviewed. Breast
density will be measured centrally using computer-assisted
software, Cumulus (University of Toronto, Toronto
Ontario, Canada), by a single observer. The density of
both breasts will be assessed by breast MRI [20], with the
cranio-caudal view of the contralateral breast used as a
reference to evaluate the percent change in mammo-
graphic density.Discussion
The maximum effective dose of metformin to treat
hyperglycemia in patients with type 2 diabetes is
1000 mg twice daily. However, the metformin dose that
yields the maximal anti-tumor effect is unclear. Results
from two xenograft models reported that the human
equivalent of 1500–2250 mg/day was needed to inhibit
tumorigenesis [21-23]. A preoperative window of oppor-
tunity trial in breast cancer patients utilized a dose of
2000 mg/day [24], whereas the ongoing NCIC CTG
MA32 phase III clinical trial is testing the effect of adjuvant
metformin, is utilizing a dosage of 1700 mg/day. To use the
maximum dose of metformin in this neoadjuvant setting,
as well as to ensure patient safety, the dose is gradually in-
creased over the first few weeks of treatment, and doses
may be adjusted in response to toxicities/adverse events.
The results of this trial will provide important information
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non-diabetic breast cancer patients.
This study was designed to evaluate the direct anti-
tumor effects of metformin in human breast cancer can-
cers. We expect that metformin will show a synergy with
neoadjuvant letrozole in ER-positive breast cancer pa-
tients similar to that of the mTOR inhibitor, everolimus.
Parallel translational research may provide a better un-
derstanding of the mechanism of action of metformin in
cancer and may reveal biomarkers predictive of response
to metformin.
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